32 ....................................................................................................................................................................................................................................................................................................................................................................................................................................................................... We are continually organizing for sustainability success and making a tangible difference in how big pharma and biotech companies meet patient unmet needs as part of their sustainability contribution. Over the past two decades, the CDMO sector has greatly advanced and is now considered an integral source of drug development and delivery. For us being integral translates into a partnership credo andhigher responsibility for committedly delivering as part of the innovation value chain. It is about being more than just a “pair of hands” but instead trusted collaborators enhancing the potential for innovative new drugs reaching patients while meeting sustainability goals. 1. Working across a diverse set of therapeutic areas, the Integrated Discovery Services team is seeking a sustainable footprint by contributing to patient-centricity The backbone of our service culture success is - reliability, consistency in team capability and communication helping us to productively deliver novel chemistry, in a faster time, with efficient iterations for the final molecule to be chosen. Sai’s Discovery services business has doubled its scientific resource pool and tripled its laboratory space for Medchem and this offers a flexible approach to fulfilling the Full-Time Equivalent (FTE) model. We are handling the development of complex, cyclic peptides conjugatedwithlinkersamongotherchemistrycapabilities.Asimilarexpansionofpeopleresourcesand laboratory space has been done for Biology in our facilities in Cambridge, Boston and in Hyderabad, India. Our growing capabilities in Electrophysiology, high content imaging and Eco dispensing systems in the Biology services space are pivotal to our client engagement. Integrated discovery services A strong track record of enduring customer relationships averaging 10+ years. which includes big pharma, mid-sized pharma, biotech’s, and startup companies including oncology, pain, inflammation, fibrosis, CNS, autoimmune and rare diseases among others Supported over 180+ discovery programs for a global clientele 18 months average turnaround time from Hit/Lead to Candidate 35+ programs advanced to different clinical phases (IND to Phase-III) Multiple therapeutic areas
RkJQdWJsaXNoZXIy MTIwMDc4NQ==